Regulation of stromal cell-derived factor-1 and exhaled nitric oxide in asthmatic children following montelukast and ketotifen treatment

Pulmonary Pharmacology and Therapeutics

Volumn 20, Issue 3, 2007, Pages 233-239

  Hung, Chih Hsing ^a,b   Jong, Yuh Jyh ^a,b   Hua, Yi Ming ^c   Li, Chi Yuan ^c   Lai, Yuan Sheng ^c   Yang, Kuender D ^d   Chang, Hui Chiu ^e  

^a Institute of Clinical Pharmacy and Pharmaceutical Sciences   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^d CHANG GUNG CHILDREN S HOSPITAL   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Exhaled nitric oxide; Ketotifen; Montelukast; Peak expiratory flow; Stromal cell derived factor 1; THP 1 cell

Indexed keywords

KETOTIFEN; KETOTIFEN FUMARATE; LIPOPOLYSACCHARIDE; MONTELUKAST; NITRIC OXIDE; STROMAL CELL DERIVED FACTOR 1; ZAFIRLUKAST;

ADOLESCENT; ARTICLE; ASTHMA; CHEMOTAXIS; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; EXPIRED AIR; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; MALE; MONOCYTE; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REGULATORY MECHANISM; TREATMENT OUTCOME;

ACETATES; ADMINISTRATION, ORAL; ADOLESCENT; ANTI-ALLERGIC AGENTS; ANTI-ASTHMATIC AGENTS; ASTHMA; BUDESONIDE; CALCIUM; CELL LINE; CELL MOVEMENT; CHEMOKINES, CXC; CHEMOTAXIS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EXHALATION; FEMALE; FLAVONOIDS; HUMANS; KETOTIFEN; MALE; MONOCYTES; NITRIC OXIDE; PEAK EXPIRATORY FLOW RATE; PROSPECTIVE STUDIES; QUINOLINES;

EID: 33846904319     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2006.03.007     Document Type: Article

References (21)

1. Coyle A.J., Wagner K., Bertrand C., et al. Central role of immunoglobulin E in the induction of lung eosinophil infiltration and T helper 2 cell cytokine production inhibition by a non-anaphylactogenic anti-IgE antibody. J Exp Med 183 (1996) 1303-1310
2. Bleul C.C., Fuhlbrigge R.C., Casasnovas J.M., et al. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor (SDF-1). J Exp Med 184 (1996) 1101-1109
3. Hoshino M., Aokie N., Takahashi M., et al. Increased immunoreactivity of stromal cell-derived factor-1 and angiogenesis in asthma. Eur Respir J 21 (2003) 804-809
4. Gonzalo J.A., Lloyd C.M., Peled A., et al. Critical involvement of the chemotactic axis CXCR4/stromal cell-derived factor-1 α in the inflammatory component of allergic airway disease. J Immunol 165 (2000) 499-508
5. Barnes P.J., Chung K.F., and Page C.P. Inflammatory mediators of asthma: an update. Pharmacol Rev 50 (1998) 515-519
6. Jatakanon A., Lim S., Kharitonov S.A., et al. Correlation between exhaled nitric oxide, sputum eosinophils and methacholine responsiveness in patient with mild asthma. Thorax 53 (1998) 91-95
7. Tsai Y.G., Lee M.Y., Yang K.D., et al. A single dose of nebulized budesonide decreases exhaled nitric oxide in children with acute asthma. J Pediatr 139 (2001) 433-437
8. Bisgaard H., Loland L., and Anhoj J. NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast. Am J Respir Crit Care Med 160 (1999) 1227-1231
9. Heyman S.N., Karmeli F., Brezis M., et al. The effect of ketotifen on nitric oxide synthase activity. Br J Pharmacol 120 (1997) 1545-1551
10. Expert Panel. Guideline for the diagnosis and management of asthma. Report 2. In: National Institutes of Health, National Heart, Lung, and Blood Institute; 1997. p. 1a-1-3.
11. Bahceciler N.N., Isik U., Barlan I.B., et al. Efficacy of sublingual immunotherapy in children with asthma and rhinitis. Pediatr Pulmonol 32 (2001) 49-55
12. 2+-dependent pathway. Am J Physiol 275 (1998) C1255-C1263
13. Bustos G.J., Bustos D., Bustos G.J., et al. Prevention of asthma with ketotifen in preasthmatic children: a three-year follow-up study. Clin Exp Allergy 25 (1995) 568-573
14. Kabra S.K., Pandey R.M., Singh R., et al. Ketotifen for asthma in children aged 5 to 15 years: a randomized placebo-controlled trial. Ann Allergy Asthma Immunol 85 (2000) 46-52
15. Croce J., Negreiros E.B., Mazzei J.A.M., et al. A double-blind, placebo-controlled comparison of sodium cromoglycate and ketotifen in the treatment of children asthma. Allergy 50 (1995) 524-527
16. Pizzichini E., Leff J.A., Reiss T.F., et al. Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, control trial. Eur Respir J 14 (1999) 12-18
17. Bleul C.C., Farzan M., Choe H., et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV entry. Nature 382 (1996) 829-833
18. Gonzalo J.A., Lloyd C., Wen D., et al. The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airway hyperresponsiveness. J Exp Med 188 (1998) 157-167
19. Jin C., Fu W.X., Xie L.P., Qian X.P., and Chen W.F. SDF-1α production is negatively regulated by mouse estrogen enhanced transcript in a mouse thymus epithelial cell line. Cell Immunol 223 (2003) 26-34
20. Maeba S., Ichiyama T., Ueno Y., Makata H., Matsubara T., and Furukawa S. Effect of montelukast on nuclear factor kappa B activation and proinflammatory molecules. Ann Allergy Asthma Immunol 94 (2005) 670-674
21. Wang J., Guan E., Roderiquez G., Calvert V., Alvarez R., and Norcross M.A. Role of tyrosine phosphorylation in ligand-independent sequestration of CXCR4 in human primary monocytes-macrophages. J Biol Chem 276 (2001) 49236-49243